Drug Resistance in Visceral Leishmaniasis

Abstract

Visceral leishmaniasis remains a public health problem worldwide. This illness was included by the World Health Organization in the list of neglected tropical diseases targeted for elimination by 2015. The widespread emergence of resistance to pentavalent antimonials in India where half cases occur globally and the unavailability of a vaccine in clinical use constitute major obstacles in achieving this goal. The last decade new antileishmanials became available, including the oral agent miltefosine. However, in poor endemic countries their wide use was curtailed because of the high costs, and also due to concerns of toxicity and emergence of resistance. Various mechanisms of antileishmanial resistance were identified recently in field isolates. Their elucidation will boost the design of new drugs and the molecular surveillance of resistance. Combination regimens should be evaluated in large trials. Overall, the development of antileishmanials has been generally slow; new drugs are needed. In order to control visceral leishmaniasis worldwide, treatment advances should become affordable in the poorest countries, where they are needed most.

Cited by papers we hold 5

• An Overview of Drug Resistance in Protozoal Diseases · 2019
  No notice
• Drug resistance and treatment failure in leishmaniasis: A 21st century challenge · 2017
  No notice
• The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases · 2016
  No notice
• The contribution of immune evasive mechanisms to parasite persistence in Visceral Leishmaniasis · 2016
  Not checked
• Leishmania donovani Nucleoside Hydrolase terminal domains in cross-protective immunotherapy against Leishmania amazonensis murine infection · 2014
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.